Face mask inactivating viruses and bacteria

该项目解决了HCW和急诊室人员对可靠、可重复使用的高级PPE的需求。具体目标是满足因COVID 19大流行而加剧的公众需求。在英国，根据皇家医师学院的数据，四分之一的医生因为生病或自我隔离而下班。在意大利，大多数感染发生在医院急诊室，原因是没有戴口罩的人太多。总体而言，10%的COVID 19感染者是HCW。这增加了NHS和其他国家卫生组织的压力，特别是在大流行期间。具体的创新 ** 是一个口罩，以防止病毒和细菌。该口罩的新奇是由来自许多不同医学领域的专业知识组合而成的。口罩不仅能过滤掉有害病原体，还能灭活它们，使病毒无法致病。该方法的独特之处在于它结合了两种主要类型的PPE的最佳方面：a）普通的基于过滤器的面罩--轻且便携，物有所值，提供了可重复使用的模型b）基于SCBA的PPE（例如危险防护服）--提供了最高等级的个人防护，适合于在高风险环境中工作。本发明是轻且便携的，同时还提供了像基于SCBA的PPE那样的增强的防护。本发明解决了基于过滤器的口罩（ssRNA病毒比最高等级的外科口罩（如N95）中的过滤器小6- 10倍）和SCBA设备的缺点，SCBA设备是一次性的并且非常昂贵。我们的目标群体包括A&E工作人员，高级护理人员和紧急医疗技术人员，流行期间的全科医生，所有其他HCW，A&E室的访客。“扩大影响”过程符合我们扩大HFEF防护口罩以达到特定市场利基的目标。额外的资金将增加创新的影响力和上市速度。我们的主要市场将是英国和美国的A&E员工和全科医生。我们采用无晶圆厂业务模式，使我们能够从较低的资本成本中获益，同时将研发资源集中在终端市场。我们的团队成员拥有实施Horizon 2020项目的经验，并提供商业和战略，营销和销售，工程和产品设计以及系列创业的独特技能组合。

The project addresses the need for reliable, re-usable, high-grade PPE for HCW and people in emergency rooms. The specific aim is to satisfy the public need exacerbated by the COVID19 pandemic. In the U.K., one in four doctors is off work because they are either sick or in self-isolation, according to the Royal College of Physicians. In Italy, most infections occurred in hospital emergency rooms due to the volume & traffic of people without masks. Overall, 10% of those infected with COVID19, were HCWs. This increases the strain on the NHS and other National Health organisations, especially during a pandemic.**The specific innovation** is a face mask for protection against viruses and bacteria. The novelty of the mask is created by a combination of know-how from a number of different medical fields. The mask does not simply filter out harmful pathogens, but also inactivates them, rendering viruses incapable of pathogenesis. The approach is unique in the way it combines the best aspects of the two main types of PPE:a) Common filter based face masks -- light and portable, value for money, offers reusable modelsb) SCBA based PPE (for example hazmat suit) -- offers the highest grade of personal protection, suitable for work in high-risk environmentsThe current invention is light and portable while also offering enhanced protection like SCBA-based PPE. The invention solves the drawbacks of filter-based masks (ssRNA viruses are 6-10X smaller than the filters in the highest grade surgical masks, like N95) and of SCBA equipment, which is single-use and exceptionally expensive.Our target groups include A&E staff, Advanced Paramedic and Emergency Medical Technicians, GPs during an epidemic, all other HCWs, visitors to A&E rooms.“Extension for Impact” process aligns with our goal to scale our HFEF protective mask to reach specific market niches. The additional funding will increases the innovation’s impact and speed to market.Our Primary market will be A&E staff and GPs in the UK and the US. We use the fabless business model allowing us to benefit from lower capital costs while concentrating their research and development resources on the end market. Our team members have experience in implementing Horizon 2020 projects and offer a unique combination of skills in business and strategy, marketing & sales, engineering, and product design, and serial entrepreneurship.